Search results
Results from the WOW.Com Content Network
CBN was the first cannabinoid to be isolated from cannabis extract in the late 1800s. Specifically, it was discovered by Barlow Wood, Newton Spivey, and Easterfield in 1896. [ 21 ] In the early 1930s, CBN's structure was identified by Cahn , [ 22 ] [ 23 ] marking the first development of a cannabis extract .
The use of THC in any capacity may lead to health concerns and users should consult medical personnel before consumption. Local and state laws for use and possession of THC vary by jurisdiction ...
Cannabinol (CBN) is a mildly psychoactive cannabinoid that acts as a low affinity partial agonist at both CB1 and CB2 receptors. [ 31 ] [ 32 ] [ 33 ] Through its mechanism of partial agonism at the CB1R, CBN is thought to interact with other kinds of neurotransmission (e.g., dopaminergic, serotonergic, cholinergic, and noradrenergic).
11-Hydroxycannabinol (11-OH-CBN) is the main active metabolite of cannabinol (CBN), one of the active components of cannabis, [1] and has also been isolated from cannabis itself. [2] It is more potent than CBN itself, acting as an agonist of CB 1 with around the same potency as THC , but is a weak antagonist at CB 2 .
Whether smoking cannabis increases cancer risk in general is difficult to establish since it is often smoked mixed with tobacco – a known carcinogen – and this complicates research. [25] Cannabis use is linked to an increased risk of a type of testicular cancer. [26] The association of cannabis use with head and neck carcinoma may differ by ...
Like Δ 9-THC, 11-hydroxy-THC is a partial agonist at the cannabinoid receptor CB 1, but with significantly higher binding affinity (K i = 0.37 nM compared to Δ 9-THC K i = 35 nM). [7] With respect to cAMP inhibition at CB 1 it displays a similar efficacy to that of Δ 9 -THC (EC 50 = 11 nM vs. EC 50 = 5.2 nM, respectively), but a lower ...
Clinical trials comparing the use of cannabis extracts with Marinol in the treatment of cancer cachexia have demonstrated equal efficacy and well-being among subjects in the two treatment arms. [41] United States federal law currently registers dronabinol as a Schedule III controlled substance , but all other cannabinoids remain Schedule I ...
Female cannabis plants contain at least 113 cannabinoids, [54] including cannabidiol (CBD), thought to be the major anticonvulsant that helps people with multiple sclerosis, [55] and cannabichromene (CBC), an anti-inflammatory which may contribute to the pain-killing effect of cannabis.